

REQUEST FOR ACCESS OF ABANDONED APPLICATION UNDER 37 CFR 1.14(a)

RECEIVED
SEP 12 2001
File Information Unit

In re Application of

Application Number

Filed

08/332046

11/1/94

Group/Art Unit

Examiner

Paper No. #39

Assistant Commissioner for Patents
Washington, DC 20231

I hereby request access under 37 CFR 1.14(a)(3)(iv) to the application file record of the above-identified ABANDONED application, which is: (CHECK ONE)

- (A) referred to in United States Patent Number 6248516 column _____
- (B) referred to in an application that is open to public inspection as set forth in 37 CFR 1.11, i.e., Application No. _____ filed _____ on page _____ of paper number _____
- (C) an application that claims the benefit of the filing date of an application that is open to public inspection, i.e., Application No. _____ filed _____ or
- (D) an application in which the applicant has filed an authorization to lay open the complete application to the public.

Please direct any correspondence concerning this request to the following address:

[Signature]
Signature

9/12/01
Date

Typed or printed name

FOR PTO USE ONLY

Approved by: [Signature]
(Initials)

Unit: F-I-4



US006248516B1

(12) **United States Patent**
Winter et al.

(10) **Patent No.:** **US 6,248,516 B1**
(45) Date of Patent: **Jun. 19, 2001**

(54) **SINGLE DOMAIN LIGANDS, RECEPTORS
 COMPRISING SAID LIGANDS METHODS
 FOR THEIR PRODUCTION, AND USE OF
 SAID LIGANDS AND RECEPTORS**

4,965,188 10/1990 Mullis et al. .
 4,978,743 12/1990 Selbeck et al. .
 4,983,728 1/1991 Herzog et al. .
 5,023,171 6/1991 Ho et al. .

(List continued on next page.)

(75) **Inventors:** Gregory Paul Winter; Elizabeth Sally
 Ward, both of Cambridge; Detlef
 Güssow, Abington, all of (GB)

(73) **Assignee:** Medical Research Council, London
 (GB)

(*) **Notice:** Subject to any disclaimer, the term of this
 patent is extended or adjusted under 35
 U.S.C. 154(b) by 0 days.

(21) **Appl. No.:** 08/470,031

(22) **Filed:** Jun. 6, 1995

FOREIGN PATENT DOCUMENTS

2016841 11/1990 (CA) .
 2019323 12/1990 (CA) .
 0 120 694 10/1984 (EP) .
 0 125 023 11/1984 (EP) .
 0 171 496 2/1986 (EP) .
 0 173 494 3/1986 (EP) .
 0 194 276 B1 9/1986 (EP) .
 0 200 362 12/1986 (EP) .
 0 201 184 B1 12/1986 (EP) .
 0 239 400 9/1987 (EP) .
 0 368 684 5/1990 (EP) .
 2 137 631 10/1984 (GB) .
 61-104788 5/1986 (JP) .
 63-152984 6/1988 (JP) .
 WO 86/01533 3/1986 (WO) .
 WO 87/02671 5/1987 (WO) .
 WO-A
 88/01649 3/1988 (WO) .
 WO 88/ 0663 9/1988 (WO) .
 WO 88/06630 9/1988 (WO) .
 WO 88/09344 12/1988 (WO) .
 WO 89/00999 2/1989 (WO) .
 WO 90/14424 11/1990 (WO) .
 WO 90/14430 11/1990 (WO) .
 WO 90/14443 11/1990 (WO) .
 WO-A
 97/08320 3/1997 (WO) .

Related U.S. Application Data

(62) Division of application No. 08/332,046, filed on Nov. 1
1994, which is a continuation of application No. 07/796,805,
filed on Nov. 25, 1991, which is a division of application No.
07/580,374, filed on Sep. 11, 1990, now abandoned.

(30) Foreign Application Priority Data

Nov. 11, 1988 (GB) 8826444
 Mar. 16, 1989 (GB) 8906034
 Apr. 22, 1989 (GB) 8909217
 May 15, 1989 (GB) 8911047
 Jun. 2, 1989 (GB) 8912652
 Jun. 16, 1989 (GB) 8913900
 Aug. 15, 1989 (GB) 8918543
 Nov. 13, 1989 (WO) PCT/GB89/01344

(51) **Int. Cl.⁷** C12Q 1/68

(52) **U.S. Cl.** 435/6; 435/69.6; 435/252.33;
 435/441; 435/446

(58) **Field of Search** 435/240.2, 252.3,
 435/252.33, 6, 69.6, 441, 446; 536/23.7,
 23.4, 23.5, 23.6

(56) References Cited

U.S. PATENT DOCUMENTS

4,356,270 10/1982 Itakura .
 4,642,334 2/1987 Moore et al. .
 4,656,134 4/1987 Ringold .
 4,683,195 7/1987 Mullis et al. .
 4,683,202 7/1987 Mullis .
 4,704,692 11/1987 Ladner .
 4,711,845 12/1987 Gelfand et al. .
 4,714,681 12/1987 Reading .
 4,800,159 1/1989 Mullis et al. .
 4,806,471 2/1989 Molin et al. .
 4,816,397 3/1989 Boss et al. .
 4,889,818 12/1989 Gelfand et al. .
 4,937,193 6/1990 Hinchliffe et al. .
 4,946,786 8/1990 Tabor et al. .
 4,959,317 9/1990 Sauer .

OTHER PUBLICATIONS

Kokubu, F., et al, *The EMBO Journal*, vol. 7, No. 7, pp.
 1979-1988, 1988 "Complete structure and organization of
 immunoglobulin heavy chain constant region genes in a
 phylogenetically primitive vertebrate".
 Schwager, J., et al, *Proc. Natl. Acad. Sci. USA*, vol. 85, pp.
 2245-2249, Apr. 1988 Immunology "Amino acid sequence
 of heavy chain from *Xenopus laevis* IgM deduced from
 cDNA sequence: Implications for evolution of immunoglo-
 bulin domains".
 Roth, M.E., et al, *Science*, vol. 241, pp. 1354-1358, Sep. 9,
 1988 "Selection of Variable-Joining Region Combinations
 in the α Chain of the T Cell Receptor".

(List continued on next page.)

Primary Examiner—James Ketter

(74) *Attorney, Agent, or Firm*—Nixon & Vanderhye PC

(57) ABSTRACT

The present invention relates to single domain ligands
 derived from molecules in the immunoglobulin (Ig)
 superfamily, receptors comprising at least one such ligand,
 methods for cloning, amplifying and expressing DNA
 sequences encoding such ligands, preferably using the poly-
 merase chain reaction, methods for the use of said DNA
 sequences in the production of Ig-type molecules and said
 ligands or receptors, and the use of said ligands or receptors
 in therapy, diagnosis and catalysis.

21 Claims, 23 Drawing Sheets